MRK.DE - Merck Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed Price. Currency in EUR
95.00
+0.49 (+0.52%)
As of 9:46AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close94.51
Open94.80
Bid95.00 x 6700
Ask95.01 x 11200
Day's Range94.74 - 95.00
52 Week Range90.00 - 115.20
Volume41,448
Avg. Volume559,897
Market Cap41.18B
BetaN/A
PE Ratio (TTM)24.77
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 18, 2017
    Capital Cubeyesterday

    Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 18, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • TheStreet.com9 days ago

    Pfizer Pops in Pre-Market After Group Considers Consumer Healthcare Sale

    Pfizer's consumer healthcare division has 10 brands, including Advil and Centrum, that had $100 million or more in sales last year.

  • Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 2, 2017
    Capital Cube17 days ago

    Merck KGaA breached its 50 day moving average in a Bearish Manner : MRK-DE : October 2, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
    Zacks27 days ago

    Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

    Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

  • Reuters28 days ago

    Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

    European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. In May, ...

  • Merck KGaA – Value Analysis (XETRA:MRK) : September 12, 2017
    Capital Cubelast month

    Merck KGaA – Value Analysis (XETRA:MRK) : September 12, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck KGaA a score of 56. Our analysis is based on comparing Merck KGaA with the following peers – Bayer AG, Hutchison China MediTech Limited, Sanofi and Chemical Works of Gedeon Richter Plc (BAYN-DE, HCM-GB, SNW-DE and RIG2-DE). Investment Outlook Merck KGaA has a fundamental score of ... Read more (Read more...)

  • Nestle's Growth Supplements
    Bloomberglast month

    Nestle's Growth Supplements

    Merck's consumer-health business isn't an obvious way to buy durable growth.

  • Merck KGaA breached its 50 day moving average in a Bullish Manner : MRK-DE : September 11, 2017
    Capital Cubelast month

    Merck KGaA breached its 50 day moving average in a Bullish Manner : MRK-DE : September 11, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Reuterslast month

    Germany's Merck hires JP Morgan to sell consumer health

    FRANKFURT/LONDON, Sept 8 (Reuters) - Germany's Merck KGaA has hired JP Morgan to sell its consumer health business, which includes brands such as Seven Seas vitamins and could be worth around $4.5 billion. The family-controlled drugmaker said on Tuesday it was considering selling the business, whose sales of over-the-counter medicines and vitamin supplements are about $1 billion a year, to help fund research into higher-margin prescription drugs.

  • The Wall Street Journallast month

    Germany’s Merck Puts Consumer Drugs Business on the Block

    Merck KGaA Chief Executive Stefan Oschmann put the Germany company’s consumer-health unit on the block in a move that will focus its health-care activities on the riskier business of developing prescription ...

  • Slimming Down Will Flatter Merck KGaA
    Bloomberglast month

    Slimming Down Will Flatter Merck KGaA

    Ditching its laggard consumer-products unit can help it focus on its new cancer drug.

  • MarketWatchlast month

    Merck rises 2% after health business is put up for sale

    Shares of Merck KGaA climbed 2% in Frankfurt on Tuesday after the German pharmaceutical major put its consumer health business up for sale. In a statement the company said it's "preparing strategic ...

  • TheStreet.comlast month

    Merck KGaA Plans Consumer Healthcare Sale After Strategic Review

    Germany's Merck KGaA is looking to sell its $1 billion consumer healthcare unit after a group-wide strategic review.

  • Market Realist2 months ago

    Pfizer’s Immuno-Oncology Clinical Program’s Long-Term Growth Potential

    The success in ongoing clinical trials could help Pfizer and Merck KGaA file for label expansion and approval of the new indications for Bavencio.

  • Market Realist2 months ago

    How Merck Performed in 2Q17

    In 2Q17, Merck reported GAAP earnings per share of $0.71 compared to $0.56 in 1Q17.

  • The Wall Street Journal2 months ago

    [$$] U.K. Biotech Macrophage Gets Merck Backing

    Macrophage Pharma Ltd. has added Merck Ventures to its Series A syndicate ahead of plans to launch clinical studies of a new approach to orchestrating an immune system attack on cancer.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MRK.DE earnings conference call or presentation 3-Aug-17 12:00pm GMT

    Half Year 2017 Merck KGaA Earnings Call

  • Merck KGaA (MKGAF) Q2 Earnings Up Y/Y
    Zacks3 months ago

    Merck KGaA (MKGAF) Q2 Earnings Up Y/Y

    Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.

  • What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?
    Zacks3 months ago

    What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

    Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

  • EU charges Merck KGaA, GE, Canon over merger rules
    Reuters3 months ago

    EU charges Merck KGaA, GE, Canon over merger rules

    General Electric (GE.N), German drugmaker Merck KGaA (MRCG.DE), and Japan's Canon (7751.T) risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals. The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules. While the charges will not affect the EU approvals of the deals, they could lead to fines of up to 1 percent of global revenue for Merck KGaA and General Electric, and up to 10 percent for Canon.

  • Reuters3 months ago

    EU charges Merck KGaA, GE, Canon over merger rules

    General Electric, German drugmaker Merck KGaA, and Japan's Canon risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals. The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules. While the charges will not affect the EU approvals of the deals, they could lead to fines of up to 1 percent of global revenue for Merck KGaA and General Electric, and up to 10 percent for Canon.

  • Reuters4 months ago

    Germany's Merck gets EU backing for oral MS drug

    Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed. The European Medicines Agency, the EU's drugs regulator, said on Friday its experts had come out in favour of approving cladribine, branded as Mavenclad, for the treatment of the relapsing forms of MS. The European Commission, which has the final word, typically adopts the experts' view.

  • Capital Cube4 months ago

    Merck KGaA – Value Analysis (XETRA:MRK) : June 19, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck KGaA a score of 53. Our analysis is based on comparing Merck KGaA with the following peers – Bayer AG, Hutchison China MediTech Limited, Sanofi and Chemical Works of Gedeon Richter Plc (BAYN-DE, HCM-GB, SNW-DE and RIG2-DE). Investment Outlook Merck KGaA has a fundamental score of ... Read more (Read more...)

  • Merck KGaA breached its 50 day moving average in a Bullish Manner : MRK-DE : June 16, 2017
    Capital Cube4 months ago

    Merck KGaA breached its 50 day moving average in a Bullish Manner : MRK-DE : June 16, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)